Pharma BD Deal Intelligence
A $2.4B acquisition that gave Johnson & Johnson its Janssen Vaccines center via Crucell. The deal achieved its stated rationale, scoring well on strategic fit and pipeline outcome despite a middling financial return.
J&J / Crucell: Achieved Stated Rationale (Score: 75/100)
Full analysis, sources & comparables →J&J acquired Crucell for $2.4B as a vaccine center, later called Janssen Vaccines.
Johnson and Johnson completes tender offer for Crucell and declares offer unconditional acquiring the Dutch vaccine group to strengthen Janssen division.
Johnson and Johnson acquires vaccine developer Crucell with 58 percent premium to strengthen its biologics and vaccine pipeline capabilities.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J acquired Crucell for $2.4B as a vaccine center, later called Janssen Vaccines.
J&J / Crucell: Achieved Stated Rationale (Score: 75/100)
Assessment window: 5yr post-close.
$24.0B Global Vaccine Market (2010) · $2.4B Acquisition Price
Crucell was a Netherlands-based vaccine specialist with hepatitis B, influenza, and Quinvaxem (pentavalent childhood vaccine). J&J's $2.4B acquisition created Janssen Vaccines, establishing a dedicated vaccines R&D center and the Ad26 viral vector platform.
Janssen Vaccines developed the Ad26 platform yielding the J&J COVID-19 vaccine (2021) and Ebola vaccine (Zabdeno+Mvabea, EU 2020). The acquisition proved prescient during COVID-19, though the J&J vaccine had lower uptake than mRNA alternatives.
Johnson & Johnson closes acquisition/merger of Crucell NV for $2.4B, establishing strategic position and initiating integration.
Strategic Fit: 82/100 | Financial Return: 70/100 | Pipeline Outcome: 80/100 | Integration: 75/100 | Deal Difficulty: 45/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Crucell NV (this deal) | 2003 | $2.4B | 75 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2003 deals · Johnson & Johnson deals · Infectious Disease deals